Speaker(s): 

David Ermak, MD, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Anthony Noto, MD, Resident, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Evaluate the differences in outcomes of iPCAO between  BMM and endovascular treatment
• Develop an approach to the management of iPCAO

 Follow up Questions: 

• What is/are the factor(s) that might influence a decision to send an iPCAO for endovascular treatment?
• Are there differences in functional outcomes at 90 days between the treatment groups?
• What are the risks associated with endovascular treatment for iPCAO?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anthony Noto, MD, David Ermak, DO, Lisa Wasko, BSN, RN, SCRN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None